세계의 스타가르트병 치료제 시장(2023-2030년)

Market Overview

The Global Stargardt Disease Therapeutics Market reached US$ 197.1 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,385.6 million by 2030. The global Stargardt Disease Therapeutics market is expected to exhibit a CAGR of 28.8% during the forecast period (2023-2030).

The part of the retina that is responsible for clear, central vision, the macula, is harmed by Stargardt disease, an inherited eye condition. It often first appears throughout childhood or adolescence and over time may cause progressive visual loss. While there is now no treatment for Stargardt disease, there has been substantial advancement in the creation of therapeutic strategies to control the condition and maybe halt its development.

Market Dynamics

Advancement in Therapy Is Boosting The Global Stargardt Disease Therapeutics Market Growth During The Forecast Period.

To advance the therapy into and through a clinical study and out to the patients who need it, Opsis Therapeutics was recently founded, two layers make up the patch. One layer will act as a precursor for photoreceptors that enable vision. The stem cells in this layer will develop into photoreceptors after transplantation.

Mature retinal pigment epithelial (RPE) cells, which provide food and waste removal for photoreceptors, will make up the other layer. The backbone of the patch's structure will be a thin plastic film. The cells will be shielded and the layers will be held together by a biodegradable gel.

Stem Cell Therapy Provides The Global Stargardt Disease Therapeutics Market Growth Opportunities

Utilizing stem cells to repair damaged retinal cells is another area of development. Retinal pigment epithelium (RPE) cells can be developed from induced pluripotent stem cells (iPSCs) produced from a patient's own cells and re-implanted into the eye. In animal research, this method has shown promise for replacing sick or damaged cells, and clinical trials are now being conducted to determine its safety and effectiveness in people.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the Stargardt disease therapeutics market. Due to limitations on patient recruitment, restricted access to healthcare facilities, and the prioritization of resources towards COVID-19, the pandemic has disrupted current clinical trials across the globe. This setback might have slowed down the development of clinical trials for treatments for Stargardt's illness, thereby increasing the amount of time needed for regulatory clearances and market entry.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the Stargardt disease therapeutics market is complex and multifaceted. Healthcare facilities, including as hospitals, clinics, and research institutes, may have been destroyed or made inaccessible in areas directly impacted by the conflict. The capacity to deliver healthcare, perform clinical trials, or conduct research on Stargardt Disease Therapeutics may be impacted by this disruption.

Segment Analysis

The global Stargardt disease therapeutics market is segmented based on drug type, age group, distribution channel, and region.

The LBS-008 Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.

The LBS-008 segment accounted for the highest market stake accounting for approximately 54.3% of the Stargardt disease therapeutics market in 2022. LBS-008, or Tinlarebant, If approved, would offer a cutting-edge therapy alternative where none now exists. To prevent the buildup of harmful vitamin A byproducts in ocular tissue, LBS-008 is an oral once-daily medication that can lower and sustain the distribution of vitamin A (retinol) to the eye.

The capacity of LBS-008 to decrease and maintain the level of serum retinol-binding protein 4, or RBP4, which transports retinol from the liver to the eye, results in this effect. LBS-008 has proven its target specificity and potency in clinical trials, and according to researchers, it may have clinical value for treating Stargardt (STGD1) patients.

Geographical Analysis

The Increasing Number Of Patients with Stargardt disease, and Advancement in Stargardt Disease Therapeutics Dominate The North American Region.

North America is expected to dominate the Stargardt disease therapeutics market, accounting for around 42.7% of this market. This disorder affects about 1 in 10,000 persons. In the United States, there are 30,000 to 200,000 persons who have Stargardt illness. With several academic institutions and research organizations actively pursuing improvements in the field of ophthalmology, North America is a hotspot for scientific research and development. These organizations work together with pharma companies and other stakeholders to provide cutting-edge treatments for Stargardt's illness.

Competitive Landscape

The major global players in the market include: Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., and F. Hoffmann-La Roche AG among others.

Why Purchase the Report?

• To visualize the global Stargardt disease therapeutics market segmentation based on the product, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Stargardt disease therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Stargardt disease therapeutics market report would provide approximately 61 tables, 55 figures, and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing research activities
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of professionals
  • 4.1.3. Opportunity
    • 4.1.3.1. Advancement in therapy
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Drug Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.1.2. Market Attractiveness Index, By Drug Type
• 9.2. LBS-008*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Emixustat

10. By Age Group

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.1.2. Market Attractiveness Index, By Age Group
• 10.2. Children*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Adult

11. By Distribution Channel

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
• 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Kubota Pharmaceutical Holdings Co., Ltd.*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Stargazer Pharmaceuticals Inc
• 14.3. Sanofi S.A.
• 14.4. Alkeus Pharmaceuticals Inc
• 14.5. Astellas Pharma Inc.
• 14.6. CHABiotech CO., Ltd.
• 14.7. ReVision Therapeutics, Inc.
• 14.8. Lin BioScience, Inc.
• 14.9. Biogen Inc.
• 14.10. F. Hoffmann-La Roche AG

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us